Luye Pharma Group Ltd.

Symbol: 2186.HK




Market price today

  • 30.7442

    P/E Ratio

  • 2.7760

    PEG Ratio

  • 11.36B

    MRK Cap

  • 0.00%

    DIV Yield

Luye Pharma Group Ltd. (2186-HK) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Dian Bo Liu
Full-time employees:5005
Address:No. 15 Chuang Ye Road

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

General Outlook

In simple terms, Luye Pharma Group Ltd. has 3761.67 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.669% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.085%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.068%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.012% return, is a testament to Luye Pharma Group Ltd.'s adeptness in optimizing resource deployment. Luye Pharma Group Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.028%. Furthermore, the proficiency of Luye Pharma Group Ltd. in capital utilization is underscored by a remarkable 0.025% return on capital employed.

Stock Prices

Luye Pharma Group Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.93, while its low point bottomed out at $2.81. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Luye Pharma Group Ltd.'s stock market.

Liquidity Ratios

Analyzing 2186.HK liquidity ratios reveals its financial health of the firm. The current ratio of 114.91% gauges short-term asset coverage for liabilities. The quick ratio (88.48%) assesses immediate liquidity, while the cash ratio (39.21%) indicates cash reserves.

Current Ratio114.91%
Quick Ratio88.48%
Cash Ratio39.21%

Profitability Ratios

2186.HK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 8.42% underscores its earnings before tax deductions. The effective tax rate stands at 24.13%, revealing its tax efficiency. The net income per EBT, 80.78%, and the EBT per EBIT, 99.47%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 8.46%, we grasp its operational profitability.

Pretax Profit Margin8.42%
Effective Tax Rate24.13%
Net Income per EBT80.78%
EBT per EBIT99.47%
EBIT per Revenue8.46%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.15, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding88
Days of Inventory Outstanding198
Operating Cycle376.63
Days of Payables Outstanding164
Cash Conversion Cycle213
Receivables Turnover2.04
Payables Turnover2.23
Inventory Turnover1.84
Fixed Asset Turnover0.89
Asset Turnover0.17

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.33, and free cash flow per share, 0.09, depict cash generation on a per-share basis. The cash per share value, 2.14, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.27, offers insight into cash flow relative to sales.

Operating Cash Flow per Share0.33
Free Cash Flow per Share0.09
Cash per Share2.14
Operating Cash Flow Sales Ratio0.27
Free Cash Flow to Operating Cash Flow Ratio0.28
Cash Flow Coverage Ratio0.12
Short Term Coverage Ratio0.16
Capital Expenditure Coverage Ratio1.39
Dividend Paid and Capex Coverage Ratio1.39

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 37.52%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.87, we discern the balance between debt and equity financing. The long-term debt to capitalization, 15.68%, and total debt to capitalization, 46.54%, ratios shed light on its capital structure. An interest coverage of 0.59 indicates its ability to manage interest expenses.

Debt Ratio37.52%
Debt Equity Ratio0.87
Long Term Debt to Capitalization15.68%
Total Debt to Capitalization46.54%
Interest Coverage0.59
Cash Flow to Debt Ratio0.12
Company Equity Multiplier2.32

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.72, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.17, reflects the portion of profit attributed to each share. The book value per share, 2.92, represents the net asset value distributed per share, while the tangible book value per share, 1.16, excludes intangible assets.

Revenue Per Share1.72
Net Income Per Share0.17
Book Value Per Share2.92
Tangible Book Value Per Share1.16
Shareholders Equity Per Share2.92
Interest Debt Per Share2.75
Capex Per Share-0.33

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 15.03%, indicates top-line expansion, while the gross profit growth, 21.90%, reveals profitability trends. EBIT growth, 213.96%, and operating income growth, 213.96%, offer insights into operational profitability progression. The net income growth, 517.73%, showcases bottom-line expansion, and the EPS growth, 504.76%, measures the growth in earnings per share.

Revenue Growth15.03%
Gross Profit Growth21.90%
EBIT Growth213.96%
Operating Income Growth213.96%
Net Income Growth517.73%
EPS Growth504.76%
EPS Diluted Growth504.76%
Weighted Average Shares Growth1.03%
Weighted Average Shares Diluted Growth1.03%
Operating Cash Flow Growth806.83%
Free Cash Flow Growth136.06%
10-Year Revenue Growth per Share-66.33%
5-Year Revenue Growth per Share46.74%
3-Year Revenue Growth per Share-13.41%
10-Year Operating CF Growth per Share-46.62%
5-Year Operating CF Growth per Share60.53%
3-Year Operating CF Growth per Share-12.77%
10-Year Net Income Growth per Share-72.43%
5-Year Net Income Growth per Share-42.33%
3-Year Net Income Growth per Share-62.10%
10-Year Shareholders Equity Growth per Share-18.57%
5-Year Shareholders Equity Growth per Share40.70%
3-Year Shareholders Equity Growth per Share1.53%
5-Year Dividend per Share Growth per Share-100.00%
3-Year Dividend per Share Growth per Share-100.00%
Receivables Growth1.05%
Inventory Growth3.56%
Asset Growth7.38%
Book Value per Share Growth18.66%
Debt Growth-4.07%
R&D Expense Growth25.50%
SGA Expenses Growth5.58%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 18,031,403,373.305, captures the company's total value, considering both debt and equity. Income quality, 2.47, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.10, gauges operational efficiency, while the research and development to revenue, 14.33%, highlights investment in innovation. The ratio of intangibles to total assets, 28.82%, indicates the value of non-physical assets, and capex to operating cash flow, -70.36%, measures reinvestment capability.

Enterprise Value18,031,403,373.305
Income Quality2.47
Sales General and Administrative to Revenue0.10
Research and Development to Revenue14.33%
Intangibles to Total Assets28.82%
Capex to Operating Cash Flow-70.36%
Capex to Revenue-19.45%
Capex to Depreciation-173.34%
Stock-Based Compensation to Revenue0.43%
Graham Number3.38
Return on Tangible Assets3.50%
Graham Net Net-1.71
Working Capital1,298,610,000
Tangible Asset Value4,053,667,000
Net Current Asset Value-2,422,090,000
Invested Capital1
Average Receivables1,774,391,000
Average Payables565,417,000
Average Inventory759,641,500
Days Sales Outstanding109
Days Payables Outstanding111
Days of Inventory On Hand153

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.82, and the price to book ratio, 0.82, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.13, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 27.79, and price to operating cash flows, 7.69, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.82
Price to Book Ratio0.82
Price to Sales Ratio2.13
Price Cash Flow Ratio7.69
Price Earnings to Growth Ratio2.78
Enterprise Value Multiple4.80
Price Fair Value0.82
Price to Operating Cash Flow Ratio7.69
Price to Free Cash Flows Ratio27.79
Price to Tangible Book Ratio1.11
Enterprise Value to Sales3.01
Enterprise Value Over EBITDA9.56
EV to Operating Cash Flow10.90
Earnings Yield5.38%
Free Cash Flow Yield4.36%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Luye Pharma Group Ltd. (2186.HK) on the HKSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 30.744 in 2024.

What is the ticker symbol of Luye Pharma Group Ltd. stock?

The ticker symbol of Luye Pharma Group Ltd. stock is 2186.HK.

What is company IPO date?

IPO date of Luye Pharma Group Ltd. is 2014-07-09.

What is company current share price?

Current share price is 3.020 HKD.

What is stock market cap today?

The market cap of stock today is 11360243400.000.

What is PEG ratio in 2024?

The current 2.776 is 2.776 in 2024.

What is the number of employees in 2024?

In 2024 the company has 5005.